University of Colorado; Anschutz Cancer Pavilion

Aurora, Colorado 80045

1 studies enrolling now · 14 studies all time

What they study most

Advanced Cutaneous Melanoma, Advanced, Persistent, or Recurrent Endometrial Cancer, Atopic Dermatitis, Basal Cell Carcinoma, Cutaneous Melanoma, Epstein-Barr Virus-Associated Lymphoma, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Lymphoproliferative Disorders

Studies at this site

• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors — Recruiting now
• Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS — Completed
• Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies — Completed
• Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer — Completed
• ITIL-168 in Advanced Melanoma — Stopped early
• Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma — Completed
• A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) — Completed
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine — Completed
• Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors — Completed
• A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma — Completed
• A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis — Completed
• An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC) — Stopped early
• Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E — Stopped early
• DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma — Stopped early